EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia

Chala Kenenisa Edae iD, Abdisa Tufa Bedada, Maria Degef Teklemariam, Mesfin Bekele Tolesa, Solomon Genet Gebre

PLOS One · 2026

DOI: 10.1371/journal.pone.0340457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Chala Kenenisa Edae und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Biomedicine and Laboratory Science, Addis Ababa University, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People living with Type 2 Diabetes Mellitus (T2DM) face a heightened risk of experiencing severe complications from COVID-19, underscoring the importance of vaccination. Nonetheless, the impact of COVID-19 vaccines—especially the Johnson & Johnson (Ad26.COV2.S) vaccine—on glucose regulation has not been fully elucidated. This study evaluates the impact of vaccination on glycemic parameters, including Random Blood Sugar (RBS) and Hemoglobin A1c (HbA1c), and identifies factors influencing glycemic variability.

Methods

Between May 2023 and June 2024, a prospective cohort study was carried out at Adama Hospital Medical College in Ethiopia. Adults diagnosed with Type 2 Diabetes Mellitus were divided into two cohorts based on vaccination status: those who received the vaccine and those who did not. Glycemic parameters were recorded at baseline and subsequently at three-month intervals—specifically at 3, 6, 9, and 12 months following vaccination. To evaluate trends over time and identify influencing factors, including demographic and clinical variables, longitudinal data were analyzed using Generalized Estimating Equations (GEE).

Results

Vaccinated individuals exhibited transient elevations in RBS, peaking at three months post-vaccination before stabilizing. In contrast, HbA1c levels demonstrated a gradual increase over time. Greater glycemic variability was observed in younger individuals and females. The primary determinants of variations in glycemic levels were vaccination status, duration following immunization, and demographic characteristics. In contrast, diabetes treatments and lifestyle-related factors showed only a limited influence.

Conclusion

The Johnson & Johnson COVID-19 vaccine was associated with short-term RBS fluctuations and a sustained increase in HbA1c levels in T2DM patients. These findings highlight the need for personalized glycemic monitoring post-vaccination. Despite these metabolic variations, the vaccine’s protective role against severe COVID-19 outweighs transient glycemic disturbances. Incorporating vaccination efforts into comprehensive diabetes management is crucial, and additional studies are warranted to investigate the underlying biological mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Blood GlucoseCOVID-19COVID-19 VaccinesHumansEthiopiaFemaleProspective StudiesGlycated HemoglobinMaleBiomarkersAdultMiddle AgedSARS-CoV-2Vaccination

Substanzen

Glycated HemoglobinBlood GlucoseBiomarkersCOVID-19 Vaccineshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, School of Biomedicine and Laboratory Science, Addis Ababa University, Addis Ababa, Ethiopia.
  • Director at Adama Public Health Referral Laboratory and Research Center, Adama, Ethiopia.

ORCID-Profile: Chala Kenenisa Edae

Zitieren

APA

Edae, C. K., Bedada, A. T., Teklemariam, M. D., Tolesa, M. B., & Gebre, S. G. (2026). A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia. PLOS One. https://doi.org/10.1371/journal.pone.0340457

Vancouver

Edae CK, Bedada AT, Teklemariam MD, Tolesa MB, Gebre SG. A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia. PLOS One. 2026. doi:10.1371/journal.pone.0340457

BibTeX
@article{Edae2026,
  author = {Edae, Chala Kenenisa and Bedada, Abdisa Tufa and Teklemariam, Maria Degef and Tolesa, Mesfin Bekele and Gebre, Solomon Genet},
  title = {A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0340457}
}
Kostenlos starten →